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Abstract
Background: Oral thiopurines are effective and widely used in treatment of inflammatory bowel disease (IBD) in
humans, although their use is limited due the development of adverse events. Here, we examine the efficacy and
toxicity of oral treatment with 6-tioguanine (6-TG) and azathioprine (AZA) in a murine model of IBD.
Methods: We induced acute or chronic colitis in BALB/c mice by one or four cycles of 3% dextran sulphate
sodium (DSS), respectively. Mice were treated by daily gavages of various dosages of 6-tioguanine, azathioprine, or
by phosphate buffered saline (PBS) starting the first day of DSS or after two cycles of DSS, respectively. We
monitored the efficacy and toxicity by measuring the weight change and serum alanine aminotransferase (ALT)
activity and by disease severity and histology, at the end of the experiment. Moreover, we measured cytokine
production after colon fragment cultivation by enzyme-linked immunoabsorbent assay and numbers of apoptotic
cells in the spleen by flow cytometry.
Results: 6-TG is effective in the treatment of acute DSS-induced colitis in a dose-dependent manner and 40 μg of
6-TG is significantly more effective in the treatment of acute colitis than both AZA and PBS. This effect is
accompanied by decrease of IL-6 and IFN-g production in colon. We did not observe histological abnormalities in
liver samples from control (PBS) or 6-TG treated mice. However, liver samples from most mice treated with AZA
showed mild, yet distinct signs of hepatotoxicity. In chronic colitis, all thiopurine derivatives improved colitis, 20 μg
of 6-TG per dose was superior. High doses of 6-TG led to significant weight loss at the end of the therapy, but
none of the thiopurine derivatives increased levels of serum ALT. Both thiopurine derivatives reduced the
proportion of apoptotic T helper cells, but a high production of both IL-6 and TGF-b was observed only in colon
of AZA-treated mice.
Conclusions: Use of 6-TG in the treatment of experimental colitis in mice appears superior to AZA administration
and placebo. In contrast to 6-TG, the use of AZA resulted in histological liver abnormalities.
Background
The immune-modulating thiopurines, 6-mercaptopurine
(6-MP), and its pro-drug azathioprine (AZA), are widely
used in inflammatory bowel diseases (IBD) treatment
[1-3]. Both AZA and 6-MP require extensive metaboli-
sation before the pharmacologicaly active metabolites, 6-
thioguaninenucleotides (6-TGN), are generated.
Their mechanism of action is ascribed to both cyto-
toxic and apoptototic pathways. Owing to their struc-
tural similarity to endogenous purine bases, 6-TGN are
incorporated into DNA or RNA as fraudulent bases,
ultimately leading to cytotoxicity. Activity of the specific
metabolite, 6-thioguanine-triphosphate was recently
found to contribute to the overall molecular immuno-
suppressive effect. This end-metabolite induces apopto-
sis and decreases the expression of proinflammatory
molecules in activated T cells [4,5].
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Although thiopurine derivatives are considered to be a
relatively safe maintenance therapy, several studies
report discontinuation of thiopurine derivatives in up to
50% of patients during long-term therapy, mainly due to
the development of adverse events [6-8].
Another thiopurine, 6-tioguanine (6-TG), has been
proposed as a rescue drug for IBD patients failing to
tolerate or respond to AZA and 6-MP [9,10]. However,
this suggestion has been discouraged, when histological
liver abnormalities, in particular nodular regenerative
hyperplasia (NRH), were found in 6-TG treated IBD
patients [11,12]. These findings were verified by Ger-
man and Austrian studies [13], but not by Irish and
Dutch studies with a follow-up of 3-5 years [14-18].
Debate is ongoing whether 6-TG is potentially more
hepatotoxic than other thiopurine derivatives such as
conventional AZA or 6-MP, or whether its alleged
hepatotoxicity is dose-dependent [19]. We therefore
designed an AZA- and placebo-controlled study using
different doses of 6-TG to assess the therapeutic effi-
cacy and (hepato) toxicity in the murine model of




We used conventional female, 3-month-old BALB/c
mice (Institute of Physiology AS CR, Prague, Czech
Republic) in this study. The experiments were approved
by the Institutional animal care and use committee at
the Academy of Sciences of the Czech Republic.
Experimental design
Acute colitis was induced by 3% (weight/volume) dex-
tran sulfate sodium (DSS) (molecular weight 36-50 kDa;
MP Biomedicals, Inc.) dissolved in drinking water for 9
days. Starting from the first day of DSS administration,
we administered 6-TG in a daily dosage of 10 μg, 20 μg
or 40 μg (obtained from Mosadex C.V., Elsloo, The
Netherlands), or AZA (Imuran® Glaxo-SmithKline) in a
daily dosage of 30 μg or 60 μg. Both agents were dis-
solved in 100 μl of sterile phosphate buffered saline
(PBS) and administered by daily gavage. Control group
was treated only with PBS. Taking into account the
average mice weight, the dose per kilogram for 10 μg,
20 μg, 40 μg of 6-TG, 30 μg or 60 μg AZA was 0.45
mg/kg, 0.91 mg/kg, 1.82 mg/kg, 1.37 mg/kg or 2.73 mg/
kg, respectively.
Chronic colitis was induced by four cycles of 3% DSS
(5 days DSS, 9 days water). The treatment with daily
oral dose of either PBS, 20 μg of 6-TG, 40 μg of 6-TG
or 60 μg AZA started after the 2nd cycle of DSS, once
the chronic colitis was established. Each mouse there-
fore received during these 22 doses a cumulative dose of
either 19.8 or 39.3 mg/kg of 6-TG, or 58.1 mg/kg of
AZA, respectively.
6-TG metabolite monitoring
To analyse the concentration of 6-tioguanine nucleo-
tides in red blood cells, we collected blood samples at
the last day of experiment in EDTA. The samples were
centrifuged to isolate erythrocytes and after washing
with PBS, erythrocyte counts were done. Samples were
than stored at -80°C until analysis, performed as
described previously [20].
Assessment of colitis severity
Colitis was evaluated on the last day of the experiment by
using a disease activity index (DAI), colon length, and
histological scoring system. The DAI scores body weight
loss, stool consistency, and the presence of the blood in
the stool, as previously described by Cooper et al. [21].
Occult blood in faeces was evaluated with Faecal Occult
Blood Test (Okult-viditest Rapid; Vidia, Vestec, Czech
Republic). No deaths occurred during the experiment.
Following sacrificing, the entire colon was removed
(from caecum to anus) and placed without tension on a
ruler. Colon length was measured as an indirect marker
of inflammation. The descending colon was fixed in 4%
formalin, and stained with haematoxylin and eosin (HE)
to evaluate mucosal damage during acute colitis or with
Sirius red (Sigma-Aldrich) and Haematoxylin to evaluate
mucosal damage in chronic colitis model. The micro-
scopic findings in acute colitis were assessed semi-quan-
titatively and weighted score developed in our
laboratory for each section was obtained, ranging from 0
(no signs of colitis) to 3 (severe colitis) as described pre-
viously [22]. To describe mucosal damage in chronic
colitis model we used different scoring system to
describe, based on the scoring system validated by Die-
leman et al. [23]. Additionally, Sirius red staining was
added to score collagen deposition. Briefly, we scored
the grade of five parameters (inflammation, extent,
regeneration, crypt damage and collagen deposition).
Each of these changes was also multiplied by the per-
centage quantifying the disease involvement on cross
sections of colon: (1) 1-25%; (2) 26-50%; (3) 51-75%; (4)
76-100%. The final score was calculated by the sum of
the scores for all five parameters.
We used mouse haptoglobin enzyme-linked immu-
noabsorbent assay (ELISA; Alpco diagnostic, Salem, NH,
USA) to analyse the concentration of acute phase pro-
tein haptoglobin, a marker of inflammation, in serum of
mice with chronic colitis.
Histological assessment of liver toxicity
Livers were fixed in 4% formalin, embedded in paraffin
and stained with haematoxylin and eosin or with
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Gomori’s silver impregnation for reticulin (4 tissue sec-
tions per mice were evaluated). Two expert liver pathol-
ogists, unaware of the treatment of the mice, were asked
to meticulously evaluate the liver samples independently
with special focus on the presence of sinusoidal dilata-
tion, veno-occlusive disease, fibrosis, cirrhosis, NRH,
steatosis, necrosis and cholestasis.
Serological assessment of liver toxicity
To monitor the hepatotoxic effects in thiopurine treated
animals, we measured the alanine transaminase (ALT)
enzyme activity in serum by MaxDiscovery Alanine
Transaminase Enzymatic Assay Kit (Bio Scientific, Aus-
tin, TX, USA) according to manufacturer’s recommen-
dations. We measured ALT activity at sacrifice and/or
at the time of the 7th, 14th and 22nd dose during chronic
colitis therapy.
Analysis of cell apoptosis by Flow cytometry
Single-cell suspensions of spleen was prepared and
stained for apoptotic cells using following fluorochrome
labelled anti-mouse mAbs: CD3-FITC (BD Biosciences,
San Jose, CA, USA), CD28-PE, CD8-PerCP.Cy5.5 (all
from eBioscience, San Diego, CA, USA), CD4-Qdot®
605 and annexin V-Alexa Fluor® 647 (both Invitrogen
Corp., Carlsbad, CA, USA) according to the manufac-
turer’s recommendation. Hoechst 33258 (Sigma-Aldrich,
St. Louis, MO, USA) was added just before analysis to
stain for dead cells. Flow cytometric analysis was per-
formed on LSRII (BD Biosciences), and data were ana-
lyzed using FlowJo software (Tree Star Inc., Ashland,
OR, USA).
Cytokine production
At the end of the experiment, sections of mouse colon
were obtained, cut open longitudinally, washed in PBS
containing penicillin and streptomycin and weighed.
These tissue fragments were then cultivated for 48 h in a
humidified incubator at 37°C and 5% CO2 in RPMI-1640
(Sigma-Aldrich) containing 10% fetal bovine serum (Bio-
chrom AG, Berlin, Germany) and 1% Antibiotic-Antimy-
cotic solution (Sigma-Aldrich). The supernatants were
collected and stored at -20°C until analysis for cytokine
production. Levels of selected cytokines were determined
using commercially available ELISA sets purchased from
Invitrogen (TNF-a, TGF-b, IL-10; Invitrogen Corp.) or
R&D Systems (IFN-g, IL-6; R&D Systems Inc., Minnea-
polis, MN, USA). All tests were performed according to
the manufacturers’ recommendations.
Statistical analysis
Values are presented as mean ± standard deviation (SD).
Differences in colon length, DAI and histological score,
cell populations, ALT activity and haptoglobin levels of
multiple groups were compared with one-way analysis
of variance (ANOVA) with Tukey’s multiple comparison
test. Differences in weight change during time of multi-
ple groups were compared to the control group (PBS/
DSS) by two-way repeated measure ANOVA with Bon-
ferroni’s post-hoc test. Differences were considered sta-
tistically significant at P < 0.05. GraphPad Prism
statistical software (version 5.03, GraphPad Software,
Inc. La Jolla, CA, USA) was used for analyses.
Results
6-TG is more effective and less toxic than AZA in acute
colitis model
The dosage of 40 μg of 6-TG daily was significantly
more effective in the treatment of acute DSS colitis than
either AZA 30 or AZA 60 μg or PBS (Figure 1A-C and
Figure 2A-C). The efficacy of 6-TG therapy correlates
with 6-TG dosage, the mice treated with 40 μg of 6-TG
had significantly longer colons and lower DAI than
those treated with 10 μg of 6-TG per day.
Figure 1 Evaluation of treatment efficacy in acute DSS-induced colitis. Values are expressed as mean (bar) ± standard deviation (whisker).
(A) DAI; (B) Colon length (cm) and (C) Histological grade. The differences among experimental groups are analyzed with one-way analysis of
variance (ANOVA) with Tukey’s multiple comparison test (*P < 0.05; **P < 0.01; ***P < 0.001). Data are pool of four independent experiments;
numbers in bars indicate number of animals per group.
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The independent pathologists, unaware of prior treat-
ment, observed evident pathological changes in most
liver samples from the group of mice treated with 30 μg
(6 out of 8 samples) and 60 μg (7 out of 8 samples) of
AZA. All these samples showed pronounced fibrosis in
the pericholangitic spaces and one sample displayed
degenerative changes of hepatocytes (Figure 3).
Some discrete changes, such as slight fibrosis of peri-
cholangitic space or sparse mononuclear cells in peri-
cholangitic spaces were observed in mice treated with
10 μg (2 out of 8 samples), 20 μg (2 out of 8 samples)
and 40 μg (1 out of 8 samples) of 6-TG and in one sam-
ple from the PBS treated mice. However, all these find-
ings were considered within normal range. None of the
evaluated samples showed signs of sinusoidal dilatation,
veno-occlusive disease, NRH, steatosis, cirrhosis, necro-
sis of hepatocytes or cholestasis. The serum ALT activ-
ity was very low (ranging 20-30 U/l) in all groups (both
treated and untreated), which indicate that no clinically
significant hepatoxicity was induced in any group of
mice (data not shown). The concentration of 6-TGN in
red blood cells was below detection limit of 30 pmol/
8*108 cells.
Low-dose 6-TG is most effective in chronic colitis model
In the chronic colitis model, the therapeutic effect of
6-TG (both 20 and 40 μg/dose) expressed as preven-
tion of colon shortening, was superior to either PBS
(control) or AZA 60 (Figure 4B). However, due to the
significant weight loss in mice with high-dose 6-TG
administration, only the mice with low-dosed 6-TG
administration shoved statistically significant improve-
ment in disease activity index (Figure 4C). Interest-
ingly, the weight loss in the 6-TG 40 treated group
started to be statistically significant at the time of the
16th dose of the 6-TG (Figure 4A). There were only
minor signs (not significant) of colitis improvement in
AZA 60 treated group and there were no statistically
significant differences in serum haptoglobin concentra-
tion between the experimental groups (Figure 4D).
Figure 2 Evaluation of treatment efficacy by colon histology.
HE stained slides showing A: Healthy colon (score 0.0); B: severely
inflamed colon (score 2.0) from the control group during acute
colitis; C: colon with medium-grade acute colitis (score 1.0)
representing 6-TG treated mice. Sirius red and Haematoxylin stained
slides showing D: Healthy colon (score 0); E: colon with severe
chronic colitis (score 32) from the control group; F: colon with
medium-grade chronic colitis (score 20) representing 6-TG treated
mice
Figure 3 Evaluation of liver toxicity by histology. Normal structure is found in PBS-treated healthy (A and B), DSS/PBS-treated mice (C and D)
and DSS/6-TG-treated (E and F), whereas a slight mononuclear infiltration and pericholangic sclerosis are seen in DSS/AZA-treated mice (G and
H). (A, C, E and G: HE stain, B, D, F and H: Gomori’s silver impregnation for reticulin).
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Nevertheless, all thiopurine derivatives reduced muco-
sal damage (Figure 4E). Samples of liver after 22 thio-
purine-doses were considered normal. None of the
samples showed signs of sinusoidal dilatation, veno-
occlusive disease, NRH, steatosis, cirrhosis, or necrosis
of hepatocytes or cholestasis. Activity of ALT in serum
was normal (between 20-30 U/l) and did not increase
in any group throughout the whole treatment period,
suggesting that there was no hepatotoxicity in any
group (data not shown). The concentration of 6-TGN
in red blood cells was below detection limit of 30
pmol/8*108 cells.
6-TG and AZA changes the cytokine production in the
colon
There is a statistically significantly lower production of
IL-6 and IFN-g in DSS/6-TG 40 treated mice, as com-
pared to DSS/PBS- or DSS/AZA 60 treated mice in the
acute colitis model (Figure 5A). These changes in pro-
inflammatory cytokines correlated with severity of coli-
tis, which was much milder in DSS/6-TG treated ani-
mals. In the chronic colitis model, a decreased
production of IL-6 in DSS/6-TG 20 treated mice as
compared to either DSS/PBS- or DSS/AZA 60-treated
mice was observed (Figure 5B). Production of IL-6 in
Figure 4 Evaluation of treatment efficacy in chronic DSS-induced colitis. Values are expressed as mean (dot or bar) ± SD (whisker). (A)
Weight change during therapy. Body weight change was calculated for each mouse by dividing its body weight on the specified day by body
weight at day 0 (body weight at the beginning of therapy) and expressed as percentage. (B) DAI (C) Colon Length (cm) (D) Serum haptoglobin
concentration (mg/ml) and (E) Histological grade. The differences among experimental groups are analyzed with either two-way analysis of
variance (ANOVA) with Bonferroni post-hoc test (Weight change; *P < 0.05; **P < 0.01; ***P < 0.001 vs. PBS-treated) or one-way ANOVA with
Tukey’s multiple comparison test (*P < 0.05; **P < 0.01; ***P < 0.001). Data are pooled from two independent experiments, each with 5 mice per
group.
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DSS/6-TG 40 treated mice was intermediate between
that of DSS/PBS- and DSS/6-TG 20 treated mice, the
difference was not, however, significant. The production
of TGF-b was higher in DSS/AZA treated mice as com-
pared to either DSS/PBS- or DSS/6-TG 20 treated mice.
Concentrations of IL-10 and TNF-a were low without
any statistically significant changes. Neither 6-TG nor
AZA changed cytokine production in non-colitic ani-
mals (data not shown).
Apoptotic cells during thiopurine therapy
There is no statistically significant effect on apoptosis in
vivo during acute colitis. In chronic colitis, 6-TG
induced apoptosis of Th (CD3+CD4+CD8-) cells while
AZA did not. Early apoptotic Th (CD3+CD8-CD4
+Annexin V+Hoechst-) cells were decreased in 6-TG-
treated mice and even more in AZA-treated mice (Fig-
ure 6). A similar trend was seen in early apoptotic cyto-
toxic T (CD3+CD4-CD8+Annexin V+Hoechst-) cells
(data not shown). AZA also decreased the proportion of
early apoptotic cells (data not shown).
Discussion
We have shown that 6-TG is effective in the treatment
of colitis in mice, in a dose dependent manner, and that
a dosage of 40 μg 6-TG per day (being 1.82 mg/kg) is
superior to both AZA and placebo in acute experimen-
tal colitis therapy. Furthermore, in contrast to AZA, 6-
TG therapy does not appear to induce histological liver
damage. More precisely, slight portobiliary mononuclear
infiltration with or without pericholangitic fibrosis (but
always with well-defined interface) is an accidental find-
ing in mice of the same breed, but damage to the adja-
cent reticulin was found only in mice that had AZA
treatment. These results are in agreement with those of
Petit et al., who showed that AZA and 6-MP decreases
the viability of human hepatocytes even in clinically
relevant concentrations when human treatment is con-
sidered, while 6-TG does not [24]. This difference in
toxic effect among thiopurines could be explained by
the production of toxic metabolites generated during
the conversion of pro-drugs AZA and 6-MP to active
metabolites 6-TGN, such as 6-methylmercaptopurines
(6-MMP) which have been associated with liver test
abnormalities [25-27]. In our experiments, AZA did not
ameliorate acute colitis, as compared to 6-TG, which
may be ascribed to differences in metabolization of thio-
purine derivatives in mice as compared to humans. This
Figure 5 Cytokine production in colon. Cytokine production by
colon tissue as analysed by tissue fragment culture and measured
by ELISA in (A) Acute and (B) Chronic colitis model. Values are
expressed as mean (bar) ± SD (whisker). The differences among
experimental groups were analyzed with one-way analysis of
variance (ANOVA) with Tukey’s multiple comparison test (*P < 0.05;
**P < 0.01). Data depict one out of two independent experiments,
each with 5 mice per group.
Figure 6 The 6-TG increases the rate of apoptosis in T helper
cells in model of chronic colitis. (A) Typical plots depicting
apoptosis in gated CD3+CD4+CD8- T helper cells after the treatment
of chronic colitis with PBS, 6-TG or AZA. (B) Graphs, mean (bar) ±SD
(whisker), representing the relative proportions of CD3+CD4+CD8- T
helper cells in each quadrant. The differences among experimental
groups were analyzed with one-way ANOVA with Tukey’s multiple
comparison test (*P < 0.05; ***P < 0.001).
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may be also the reason behind our inability to detect 6-
TGN in red blood cells of mice treated with thiopurine
derivates.
Although all key enzymes are present in mice, it is dif-
ficult to compare mice pharmacology with that in
human, which makes the comparison of dosages used in
this experiment difficult compared to studies in humans.
Nevertheless, the use of AZA in mice clearly resulted in
histological liver abnormalities, while the use of 6-TG
did not. Several studies about hepatological abnormal-
ities induced by AZA or 6-MP have been recently pub-
lished, which confirmed the results we observed in this
mouse model [28-31].
The prevalence of NRH in the rest of the population
without IBD is 2.6%, while it is 6% in the thiopurine-
naïve IBD patients, 0-7% in IBD patients treated with
low dose (approx. 20 mg/day) of 6-TG and in 18%-62%
of patients with 40-80 mg/day of 6-TG [13,19,32,33].
These findings suggest that IBD itself and high dose of
6-TG, but not 6-TG in general, could be considered as
a risk factor for NRH. The treatment duration should
be also mentioned, because in human IBD, thiopurines
are often administered for years, and although it was
long enough to cause liver injury in AZA treated mice,
nine days may not be a relevant time for induction of
NRH.
Despite the fact that there were no signs of liver
damage in chronic colitis, the mice with high dose of 6-
TG had statistically significant decrease in body weight
at the end of the experiment. This is in agreement with
the fact that high doses of 6-TG can have general toxic
effects, not related to the liver in these mice. We have
not found any pathology in liver, lungs or bone marrow
even with extreme dosage of 100 μg of 6-TG daily, how-
ever, we found hypocelularity in thymus and less acti-
vated follicles with wide mantle zones and arrest of
haematopoiesis and deposition of hemosiderin in spleen
(data not shown). These changes were mostly associated
with high dose of 6-TG, and less in low dose of 6-TG
and in AZA and could represent the consequence of the
immunomodulatory properties of thiopurines.
We observed a decrease in the number of early apop-
totic cells in the spleen of AZA-treated mice during the
course of chronic colitis. This decrease was apparent in
all thiopurine-treated geoups, when we gated to (CD3
+CD4+CD8-) Th cells. Since the induction of apoptosis
in activated Th cells is considered to be mechanism of
thiopurine anti-inflammatory action in vitro [4,5], our
findings suggest the existence of compensatory mechan-
isms in vivo.
Both 6-TG and AZA changed cytokine production in
the colon of mice during inflammation. High levels of
IL-6 and IFN-g are produced in BALB/c mice during
DSS-induced inflammation as we reported previously
[22]. Since we observed a decrease in pro-inflammatory
cytokines after 6-TG therapy in the acute and, to some
extent, also in the chronic colitis model, this may corro-
borate the anti-inflammaory potential of thiopurine deri-
vatives. Increase in TGF-b production in AZA-treated
mice with chronic colitis could be caused by several
mechanisms. TGF-b has many functions in gut mucosa
homeostasis, it serves as growth factor for both epithe-
lial and mesenchymal cells facilitating repair of mucosal
injury and collagen deposition in IBD patients [34,35].
TGF-b has also important immunomodulatory func-
tions, because it can dampen the inflammation by indu-
cing Treg cells. In contrast to this, in a presence of high
levels of IL-6, TGF-b might switch T cells to Th17 cells,
thus promoting the protective immune response and
inflammation [36,37].
Since the vast majority of AZA and 6-MP-intolerant
IBD patients are able to tolerate maintenance treatment
with 6-TG, the 6-TG was proposed as an alternative
treatment of IBD in humans in case of intolerance or
lack of therapeutic effect of AZA or 6-MP
[10,14,18,38,39]. Our findings provide additional evi-
dence that low dose 6-TG might still be considered as
therapeutic option in those IBD patients who are intol-
erant or refractory to AZA or 6-MP.
Conclusions
In conclusion, the use of 6-TG in the treatment of
experimental colitis in mice appears superior to AZA
administration and placebo. Beneficial effect of 6-TG
treatment was associated with decrease in pro-inflam-
matory cytokines in colons of treated mice. Counterin-
tuitively, the thiopurines decreased the number of early
apoptotic T helper cells. Interestingly, in contrast to 6-
TG, the use of AZA resulted in histological liver
abnormalities.
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